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In the 20th century, immunologists focused much of their
attention in deciphering the mechanisms of adaptive immu-
nity.Asaconsequence,tremendousprogresswasmadeinthe
ﬁeld of adaptive immunity, including tolerance, mechanisms
of MHC restriction, the structure and function of MHC
receptors, and developmentand activation of B- and T-cells.
The reason why adaptive immunity was the major
focus of immunologists is because adaptive immunity gives
vertebrates immunity a memory and is most probably an
important aspect of human evolution—responsible not only
for enabling cognitive abilities but also general cultural ac-
complishments.
In contrast,innateimmunitywassidelined. Itwasviewed
as the most archaic of the two branches of immunity, simple
and unsophisticated. Since the discovery of phagocytes by
Ilya Mechnikov in 1882 and the investigations of Richard
Pfeiﬀer, a fellow worker of Robert Koch, on “endotoxin,”
the concept of innate immunity for almost 100 years was
that of a static and nonspeciﬁc apparatus. It was seen as an
undiﬀerentiated system, engulﬁng and digesting invaders in
contrast to the sophisticated framework of T- and B-cells
that have elaborate clonal mechanisms to form a plethora of
highly speciﬁc antibodies by DNA rearrangement.
Almost twenty years ago, Charles Janeway changed our
view of the innate immune system, by publishing “Approach-
ing the asymptote”a sp a r to ft h eCold Spring Harbor
Symposium on immune recognition. In this publication, he
predicted that there would be molecules that were encoded
in the germ line which would recognize the presence of
molecules produced by broad classes of pathogens. He
called these molecules pattern recognition receptors (PRRs)
and the ligands that they recognise, pathogen-associated
molecular patterns (PAMPs).
Janeway’s view was justiﬁed in the late 1990s with the
discovery of Toll-like receptors (TLRs) and the veriﬁcation
that the innate immune system is actually highly speciﬁc,
relying on germline-encoded pattern-recognition receptors
(PRRs) that have evolved to detect components of foreign
pathogens referred to as PAMPs. Over the years, research
studies have shown that this system is highly speciﬁc in
recognising microbial signatures; it has virtues that are
equally speciﬁc and elaborate as the features of adaptive
immunity; for example, TLR4 was found to recognise bacte-
rial lipopolysaccharide (LPS) or endotoxin; TLR2 was found
to recognise lipoteichoic acid (LTA) and peptidoglycan;
TLR3 was able to sense double-stranded viral RNA; TLR52 Mediators of Inﬂammation
was found to recognise bacterial ﬂagellin; TLR7 and TLR8
to sense single stranded viral RNA, whereas TLR9 was found
to delicately distinguish between methylated DNA from
host DNA and unmethylated DNA from microorganisms.
Subsequently, TLRs have been identiﬁed as operational
centers for both innate and adaptive immunity.
Cancer, infection, autoimmune, and allergic disorders
involve various complex signaling pathways; however, data
accumulates that TLRs are involved in all of these seemingly
diﬀerent entities.
Their ability to initiate and propagate inﬂammation
makes them attractive therapeutic targets. By understanding
TLR-induced mechanisms, we can design more targeted
therapeutic interventions for inﬂammatory disorders in the
future. The ancient system of host defense of our cells
is an outstanding target for intervention in the relentless
eﬀortsinﬁndingcures.PharmacologicalinterventioninTLR
pathways may potentially hold great therapeutic promise.
Although for the past decades corticosteroids and in some
instances antibodies were the mainstay of anti-inﬂammatory
treatment, we are now at the stage of evaluating TLR path-
way modifying molecules in human diseases; this targeted
approach will bring more speciﬁcity to the treatment of a
wide panel of disorders.
Given the body of excellent literature on TLRs in disease,
we can be very optimistic that targeting them will prove
useful in human disease. In thisspecial issue, we compiled24
interesting papers on various aspects of human disease rang-
ing from autoimmune disorders via dermatologic disease to
cardiovascular and respiratory problems, demonstrating the
impact of TLRs in a vast number of disorders and the as-
yet unrealized therapeutic potential that is awaiting to be
translated from the bench to the clinic.
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